Segnan Nereo, Senore Carlo, Andreoni Bruno, Azzoni Alberto, Bisanti Luigi, Cardelli Alessandro, Castiglione Guido, Crosta Cristiano, Ederle Andrea, Fantin Alberto, Ferrari Arnaldo, Fracchia Mario, Ferrero Franco, Gasperoni Stefano, Recchia Serafino, Risio Mauro, Rubeca Tiziana, Saracco Giorgio, Zappa Marco
CPO Piemonte, Torino, Italy.
Gastroenterology. 2007 Jun;132(7):2304-12. doi: 10.1053/j.gastro.2007.03.030. Epub 2007 Mar 21.
BACKGROUND & AIMS: We conducted a study to estimate population coverage and detection rate (DR) achievable through different strategies of colorectal cancer (CRC) screening.
A population-based multicenter randomized trial comparing 3 strategies was used: (1) biennial immunologic fecal occult blood test (FIT), (2) "once only" sigmoidoscopy (FS), and (3) "once only" colonoscopy (TC). A random sample of men and women, aged 55 to 64 years, was drawn from general practitioners' (GP) rosters. Eligible subjects, randomized within GP, were mailed a personal invitation. Nonresponders in groups 2 and 3 were invited again at 12 and 24 months. Screenees with "high-risk" distal polyps (villous component >20%, high-grade dysplasia, CRC, size >or=10 mm, >2 adenomas) at FS, or with positive FIT, were referred for TC.
The attendance rate was 32.3% (1965/6075) for FIT, 32.3% (1944/6018) for FS, 26.5% (1597/6021) for TC. FIT detected 2 patients with CRC (0.1%) and 21 with an advanced adenoma (1.1%). The corresponding figures were as follows: 12 (0.6%) and 86 (4.5%) patients, respectively, for FS; 13 (0.8%) and 100 (6.3%) patients, respectively, for TC. To detect 1 advanced neoplasm, it would be necessary to invite 264 people with FIT, 60 with FS, 53 with TC. FS would have detected 27.3% of the proximal advanced neoplasms detected at TC. Assuming the same participation rate at TC as at FS, 48 TCs would be necessary to detect 1 additional advanced neoplasm missed by FS.
When participants are offered 1 screening test, participation is lower in a TC than in an FS program. However, DR of advanced neoplasia is higher with TC.
我们开展了一项研究,以评估通过不同的结直肠癌(CRC)筛查策略可实现的人群覆盖率和检出率(DR)。
采用一项基于人群的多中心随机试验,比较3种策略:(1)每两年进行一次免疫粪便潜血试验(FIT);(2)“仅一次”乙状结肠镜检查(FS);(3)“仅一次”结肠镜检查(TC)。从全科医生(GP)的名册中随机抽取年龄在55至64岁之间的男性和女性样本。符合条件的受试者在GP内部进行随机分组后,会收到个人邀请信。第2组和第3组的无应答者在12个月和24个月时会再次收到邀请。在FS检查中发现有“高危”远端息肉(绒毛成分>20%、高级别上皮内瘤变、CRC、大小≥10 mm、>2个腺瘤)或FIT呈阳性的受检者会被转诊进行TC检查。
FIT的参与率为32.3%(1965/6075),FS为32.3%(1944/6018),TC为26.5%(1597/6021)。FIT检测出2例CRC患者(0.1%)和21例进展期腺瘤患者(1.1%)。FS的相应数字分别为12例(0.6%)和86例(4.5%)患者;TC的相应数字分别为13例(0.8%)和100例(6.3%)患者。为检测出1例进展期肿瘤,需要邀请264人进行FIT检查,60人进行FS检查,53人进行TC检查。FS能检测出TC所发现近端进展期肿瘤的27.3%。假设TC的参与率与FS相同,那么要检测出1例FS漏检的额外进展期肿瘤,需要进行48次TC检查。
当为参与者提供1次筛查检测时,TC项目的参与率低于FS项目。然而,TC对进展期肿瘤的检出率更高。